Clinical Results of the ATS Prosthetic Valve in 240 Implants and Review of the Literature
Murat Özeren MD, Orhan Veli DoGan MD, Alp Dolgun MD, Ergin Ko¨yldIrim MD, Kosym Karapinar MD, Ertan Yücel MD

The ATS valve was developed as a new-generation bileaflet prosthetic heart valve. Clinical data obtained with ATS implants are presented, together with the first two published reports of mitral valve thrombosis of the ATS valve. Previously published data are reviewed comparatively. Between September 1998 and July 2000, 240 ATS valve prostheses were implanted in 199 patients, among whom 88 (36.6%) had mitral (MVR), 70 (29.1%) aortic (AVR), and 41 (17.1%) double valve replacement (DVR). There were six early deaths (3.0%). One patient with AVR was reoperated on for periprosthetic leakage in the first postoperative week. Valve thrombosis occurred in two patients with MVR at 12 and 14 months postoperatively. The short-term outcome in 240 implants showed the ATS valve to be safe, to have a low incidence of complications, and to provide excellent hemodynamic performance.